全文获取类型
收费全文 | 349篇 |
免费 | 17篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 21篇 |
妇产科学 | 4篇 |
基础医学 | 29篇 |
口腔科学 | 7篇 |
临床医学 | 38篇 |
内科学 | 68篇 |
皮肤病学 | 8篇 |
神经病学 | 8篇 |
特种医学 | 126篇 |
外科学 | 3篇 |
综合类 | 12篇 |
预防医学 | 14篇 |
眼科学 | 4篇 |
药学 | 13篇 |
1篇 | |
肿瘤学 | 7篇 |
出版年
2021年 | 6篇 |
2020年 | 2篇 |
2018年 | 2篇 |
2016年 | 10篇 |
2015年 | 14篇 |
2014年 | 5篇 |
2013年 | 7篇 |
2012年 | 11篇 |
2011年 | 8篇 |
2010年 | 7篇 |
2009年 | 7篇 |
2008年 | 6篇 |
2007年 | 2篇 |
2006年 | 3篇 |
2005年 | 5篇 |
2004年 | 4篇 |
2003年 | 6篇 |
2002年 | 2篇 |
1999年 | 4篇 |
1998年 | 17篇 |
1997年 | 22篇 |
1996年 | 20篇 |
1995年 | 17篇 |
1994年 | 14篇 |
1993年 | 13篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 7篇 |
1989年 | 15篇 |
1988年 | 19篇 |
1987年 | 14篇 |
1986年 | 12篇 |
1985年 | 12篇 |
1984年 | 3篇 |
1982年 | 2篇 |
1981年 | 7篇 |
1979年 | 2篇 |
1978年 | 6篇 |
1968年 | 2篇 |
1967年 | 4篇 |
1966年 | 2篇 |
1964年 | 2篇 |
1961年 | 2篇 |
1959年 | 4篇 |
1958年 | 4篇 |
1957年 | 3篇 |
1956年 | 4篇 |
1955年 | 2篇 |
1954年 | 3篇 |
1953年 | 2篇 |
排序方式: 共有367条查询结果,搜索用时 15 毫秒
11.
B. O. EK M.D. D. E. W. HOLMLUND M.D. †J.-G. SJÖODIN M.D. † L. E. STEEN M.D. † 《The American journal of gastroenterology》1978,70(4):365-370
Three patients with primary neuropathic amyloidosis are reported. They were all almost totally disabled by either diarrhea and incontinentia alvi or obstipation. In all three patients enterostomies were tried as a palliative treatment and the results of the operations have been very promising. 相似文献
12.
13.
14.
Keystone EC Kavanaugh AF Sharp JT Tannenbaum H Hua Y Teoh LS Fischkoff SA Chartash EK 《Arthritis and rheumatism》2004,50(5):1400-1411
OBJECTIVE: Tumor necrosis factor (TNF) is an important proinflammatory cytokine that mediates inflammatory synovitis and articular matrix degradation in rheumatoid arthritis (RA). We investigated the ability of adalimumab, a human anti-TNF monoclonal antibody, to inhibit the progression of structural joint damage, reduce the signs and symptoms, and improve physical function in patients with active RA receiving concomitant treatment with methotrexate (MTX). METHODS: In this multicenter, 52-week, double-blind, placebo-controlled study, 619 patients with active RA who had an inadequate response to MTX were randomized to receive adalimumab 40 mg subcutaneously every other week (n = 207), adalimumab 20 mg subcutaneously every week (n = 212), or placebo (n = 200) plus concomitant MTX. The primary efficacy end points were radiographic progression at week 52 (total Sharp score by a modified method [TSS]), clinical response at week 24 (improvements of at least 20% in the American College of Rheumatology core criteria [ACR20]), and physical function at week 52 (disability index of the Health Assessment Questionnaire [HAQ]). RESULTS: At week 52, there was statistically significantly less radiographic progression, as measured by the change in TSS, in the patients receiving adalimumab either 40 mg every other week (mean +/- SD change 0.1 +/- 4.8) or 20 mg weekly (0.8 +/- 4.9) as compared with that in the placebo group (2.7 +/- 6.8) (P < or = 0.001 for each comparison). In addition, there were statistically significant changes in the components of the TSS. At week 24, ACR20 responses were achieved by 63% and 61% of patients in the adalimumab 40 mg every other week and 20 mg weekly groups, respectively, versus 30% of patients in the placebo group (P < or = 0.001 for each comparison). At week 52, ACR20 responses were achieved by 59% and 55% of patients taking adalimumab 40 mg every other week and 20 mg weekly, respectively, versus 24% of patients taking placebo (P < or = 0.001 for each comparison). At week 52, physical function as measured by the HAQ demonstrated statistically significant improvement with adalimumab 40 mg every other week and 20 mg weekly compared with placebo (mean change in HAQ score -0.59 and -0.61, respectively, versus -0.25; P < or = 0.001 for each comparison). A total of 467 patients (75.4%) completed 52 weeks of treatment. Adalimumab was generally well tolerated. Discontinuations occurred in 22.0% of adalimumab-treated patients and in 30.0% of placebo-treated patients. The rate of adverse events (both serious and nonserious) was comparable in the adalimumab and placebo groups, although the proportion of patients reporting serious infections was higher in patients receiving adalimumab (3.8%) than in those receiving placebo (0.5%) (P < or = 0.02), and was highest in the patients receiving 40 mg every other week. CONCLUSION: In this 52-week trial, adalimumab was more effective than placebo at inhibiting the progression of structural joint damage, reducing the signs and symptoms, and improving physical function in patients with active RA who had demonstrated an incomplete response to MTX. 相似文献
15.
Arrhythmogenic Evidence for Epicardial Adipose Tissue: Heart Rate Variability and Turbulence are Influenced by Epicardial Fat Thickness 下载免费PDF全文
16.
17.
Plasma levels of plasminogen activator inhibitor type-1 (PAI-1), beta- thromboglobulin (beta TG), and fibrinopeptide A (FPA) were followed over 24 hours in 30 patients treated with alteplase for acute myocardial infarction. Samples were taken at baseline (T Oh), after 90 minutes (under alteplase, no heparin, T 1.5h), after 120 minutes (under alteplase and heparin, T 2h), 30 minutes after thrombolytic therapy (T 3.5h), as well as 12 hours (T 12h) and 24 hours (T 24h) after baseline. PAI-1 antigen levels (55 +/- 9 ng/mL at T Oh, mean +/- SEM) decreased to 35 +/- 5 (T 1.5h) and 40 +/- 6 (T 2h) ng/mL under alteplase, before increasing to 84 +/- 22 (T 3.5h), 130 +/- 30 (T 12h), and 64 +/- 7 (T 24h) ng/mL after therapy, P less than .001. A high baseline PAI-1 activity (18 +/- 3 ng/mL) decreased to 2.0 +/- 0.4 (T 1.5h) and 1.7 +/- 0.2 (T 2h) under alteplase and increased to 32 +/- 5 (T 12h) and 19 +/- 3 (T 24h) ng/mL after therapy (P less than .0001). beta TG levels (339 +/- 105 ng/mL at T Oh) decreased to 203 +/- 48 (T 2h), 154 +/- 51 (T 3.5h), 187 +/- 40 (T 12h), and 142 +/- 32 (T 24h) ng/mL under heparin (P less than .01). FPA levels (34 +/- 9 ng/mL at T Oh) increased to 85 +/- 15 ng/mL under alteplase alone (T 1.5h) and normalized under heparin (11 +/- 4, 6 +/- 2, 4 +/- 2, and 3 +/- 1 ng/mL at T 2h, T 3.5h, T 12h, and T 24h, respectively). A high level of FPA at T 3.5h correlated with reocclusion (33 +/- 12 ng/mL, n = 4 v 2.9 +/- 0.5 ng/mL, n = 21, P less than .005). We conclude that plasma levels of PAI- 1 antigen as well as activity markedly increase after alteplase therapy of acute myocardial infarction. The high activity of PAI-1 and decreasing beta TG levels suggest that platelets do not contribute significantly to this phenomenon. The marked increase of FPA levels under recombinant tissue-type plasminogen activator alone and its normalization under heparin emphasize the important role of concomitant anticoagulation in controlling further intravasal fibrin generation under alteplase. 相似文献
18.
19.
20.
EK Greisenegger N Novak L Maintz T Bieber F Zimprich D Haubenberger A Gleiss G Stingl T Kopp A Zimprich 《Journal of the European Academy of Dermatology and Venereology》2010,24(5):607-610
Background Recently, mutations in the filaggrin gene (FLG) have been shown to be a major predisposing factor for atopic dermatitis (AD). Objective In this study, we evaluated the influence of four prevalent mutations (R501X, 2282del4, R2447X and S3247X) in a large cohort of 462 Austrian and German AD patients and in 402 control individuals. Results We found a strong association of the FLG mutations with AD. Subgroup analysis revealed a significantly higher proportion of patients with an early age of disease onset and significantly higher median serum IgE levels among mutation carriers. Furthermore, we observed an overrepresentation of null alleles in AD patients with concomitant asthma compared with those without this co‐morbidity. Conclusion Our data confirm and extend the knowledge of the influence of FLG mutations in AD. 相似文献